NR4A1 and breast carcinoma: Numerous groups are currently documenting molecular evolution in hormone receptor-positive disease, and current evidence indicates that ESR1 is mutated (base pair, amplification, and fusion) in up to 50% of advanced endocrine-resistant breast cancers.